Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636545 · ClinicalTrials.gov registry record · Phase 1
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
A Phase 1 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00636545: Completed Phase 1 study, sponsored by Genta Incorporated.
NCT00636545 is a Phase 1 study that has completed, run by Genta Incorporated. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00636545, a Phase 1 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective is to determine the safety and maximum tolerated dose (MTD) of Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly (Part 2) to patients with solid tumors.
Interventions
- DRUG Oblimersen (Genasense)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
What the finished NCT00636545 record still lists
NCT00636545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Oblimersen (Genasense) is the first listed.
NCT00636545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00636545 about?
NCT00636545 is a clinical study titled "Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors". The primary objective is to determine the safety and maximum tolerated dose (MTD) of Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly (Part 2) to patients with solid tumors.
What is the current status of trial NCT00636545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00636545?
The interventions under investigation include: Oblimersen (Genasense) (DRUG).
Who is sponsoring clinical trial NCT00636545?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00636545's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia